Table 1

Patient demographics

Baseline characteristicsN=18
Age (years)
 Median (range)71.6 (54–88)
Race
 White/Caucasian15
 Black3
ECOG PS (N, %)
 07
 111
Gleason score
 Median (range)8 (6–9)
Baseline PSA (ng/mL) (range)25.58 (0.62–1006)
Prior therapies
 Chemotherapy (CSPC)10
 Chemotherapy (CRPC)6
 Therapeutic cancer vaccine7
 Immune checkpoint inhibitor6
 Abiraterone12
 Enzalutamide12
 PARP inhibitors4
 ADT only (mCRPC treatment-naïve)5
Number of prior mCRPC therapies
 Median (range)3 (0–7)
  • ADT, androgen-deprivation therapy; CRPC, castration-resistant prostate cancer; CSPC, castration-sensitive prostate cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Score; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly ADP ribose polymerase; PSA, prostate-specific antigen.